{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:26:43Z","timestamp":1792772803393,"version":"4.5.0"},"reference-count":51,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program","award":["2021YFE0206300"],"award-info":[{"award-number":["2021YFE0206300"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473400"],"award-info":[{"award-number":["82473400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Yiyang Healthcare Charity Foundation","award":["JZ2024077"],"award-info":[{"award-number":["JZ2024077"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/jitc-2026-016269","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:45:32Z","timestamp":1792763132000},"page":"e016269","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Sintilimab plus eribulin and carboplatin in patients with metastatic triple-negative breast cancer (SECURE): a phase II, multicenter trial"],"prefix":"10.1136","volume":"14","author":[{"given":"Mengqian","family":"Ni","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadi","family":"Shi","sequence":"additional","affiliation":[{"name":"Cancer Hospital, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7195-1300","authenticated-orcid":false,"given":"Meiting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daining","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Dun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingru","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Hospital, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkui","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Breast, Bone and Soft Tissue Oncology, Guangxi Medical University Cancer Hospital, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-8049","authenticated-orcid":false,"given":"Yanxia","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-5511","authenticated-orcid":false,"given":"Xin","family":"An","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"2026102306452550000_14.10.e016269.1","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-019-1210-4","article-title":"Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review","volume":"21","author":"Li","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2026102306452550000_14.10.e016269.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465"},{"key":"2026102306452550000_14.10.e016269.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"2026102306452550000_14.10.e016269.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"2026102306452550000_14.10.e016269.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"2026102306452550000_14.10.e016269.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355"},{"key":"2026102306452550000_14.10.e016269.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.801"},{"key":"2026102306452550000_14.10.e016269.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4"},{"key":"2026102306452550000_14.10.e016269.9","doi-asserted-by":"crossref","first-page":"102283","DOI":"10.1016\/j.ctrv.2021.102283","article-title":"Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis","volume":"100","author":"Saleh","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2026102306452550000_14.10.e016269.10","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/CAD.0000000000001196","article-title":"A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer","volume":"33","author":"Feng","year":"2022","journal-title":"Anticancer Drugs"},{"key":"2026102306452550000_14.10.e016269.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.009"},{"key":"2026102306452550000_14.10.e016269.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.0572"},{"key":"2026102306452550000_14.10.e016269.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01506"},{"key":"2026102306452550000_14.10.e016269.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70064-1"},{"key":"2026102306452550000_14.10.e016269.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31704-7","article-title":"A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"2026102306452550000_14.10.e016269.16","doi-asserted-by":"publisher","DOI":"10.3390\/md13085016"},{"key":"2026102306452550000_14.10.e016269.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3252"},{"key":"2026102306452550000_14.10.e016269.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"2026102306452550000_14.10.e016269.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4892"},{"key":"2026102306452550000_14.10.e016269.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3144-y"},{"key":"2026102306452550000_14.10.e016269.21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejca.2017.10.002","article-title":"Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer","volume":"86","author":"Park","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026102306452550000_14.10.e016269.22","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO-24-01888","article-title":"Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced\/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial","volume":"43","author":"Yamashita","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026102306452550000_14.10.e016269.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3435-y"},{"key":"2026102306452550000_14.10.e016269.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-12953-9","article-title":"Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study","volume":"24","author":"Ni","year":"2024","journal-title":"BMC Cancer"},{"key":"2026102306452550000_14.10.e016269.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4726"},{"key":"2026102306452550000_14.10.e016269.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0638-x"},{"key":"2026102306452550000_14.10.e016269.27","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA119.001714"},{"key":"2026102306452550000_14.10.e016269.28","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3317"},{"key":"2026102306452550000_14.10.e016269.29","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1226"},{"key":"2026102306452550000_14.10.e016269.30","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol"},{"key":"2026102306452550000_14.10.e016269.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3141"},{"key":"2026102306452550000_14.10.e016269.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2012.03.044"},{"key":"2026102306452550000_14.10.e016269.33","first-page":"473","article-title":"T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer","volume":"10","author":"Fu","year":"2020","journal-title":"Am J Cancer Res"},{"key":"2026102306452550000_14.10.e016269.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0881"},{"key":"2026102306452550000_14.10.e016269.35","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.122"},{"key":"2026102306452550000_14.10.e016269.36","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.80"},{"key":"2026102306452550000_14.10.e016269.37","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent updates on Sintilimab in solid tumor immunotherapy","volume":"8","author":"Liu","year":"2020","journal-title":"Biomark Res"},{"key":"2026102306452550000_14.10.e016269.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02086"},{"key":"2026102306452550000_14.10.e016269.39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772450","article-title":"The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"2026102306452550000_14.10.e016269.40","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100094","article-title":"Impact of the combined timing of PD-1\/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer","volume":"6","author":"Yao","year":"2021","journal-title":"ESMO Open"},{"key":"2026102306452550000_14.10.e016269.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1298"},{"key":"2026102306452550000_14.10.e016269.42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1545"},{"key":"2026102306452550000_14.10.e016269.43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011314","article-title":"Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026102306452550000_14.10.e016269.44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010158","article-title":"Correlation of safety and efficacy of atezolizumab therapy across indications","volume":"12","author":"Dur\u00e1n-Pacheco","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026102306452550000_14.10.e016269.45","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0120","article-title":"Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients","volume":"31","author":"Villanova","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"2026102306452550000_14.10.e016269.46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2024.255","article-title":"Role of HIF-1\u03b1 in the Responses of Tumors to Radiotherapy and Chemotherapy","volume":"57","author":"Song","year":"2025","journal-title":"Cancer Res Treat"},{"key":"2026102306452550000_14.10.e016269.47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159473","article-title":"Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy","volume":"132","author":"Shurin","year":"2022","journal-title":"J Clin Invest"},{"key":"2026102306452550000_14.10.e016269.48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3892\/ijo.2017.3867","article-title":"Inhibition of FASN suppresses migration, invasion and growth in hepatoma carcinoma cells by deregulating the HIF-1\u03b1\/IGFBP1 pathway","volume":"50","author":"Gong","year":"2017","journal-title":"Int J Oncol"},{"key":"2026102306452550000_14.10.e016269.49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3227"},{"key":"2026102306452550000_14.10.e016269.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.007"},{"key":"2026102306452550000_14.10.e016269.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4572"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-016269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:45:36Z","timestamp":1792763136000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-016269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,23]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jitc-2026-016269"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-016269","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}